Marco Davila, MD, PhD, the senior vice president and associate director for Translational Research in the Department of Medicine, as well as the Rustum Family Endowed Chair in Translational Research at Roswell Park Comprehensive Cancer Center
Dr. Joshua Richter and Dr. Marco Davila conclude the discussion by reflecting on the future of relapsed/refractory multiple myeloma (RRMM) and the rapid evolution of cellular therapies and other novel treatment options.
Dr. Joshua Richter and Dr. Marco Davila discuss practical considerations for holding and bridging therapy in patients with relapsed/refractory multiple myeloma (RRMM) who are preparing to receive CAR T-cell therapy.
Dr. Joshua Richter and Dr. Marco Davila discuss a case of a patient with relapsed/refractory multiple myeloma (RRMM) who has high-risk, rapidly progressive disease but faces practical barriers to receiving CAR T-cell therapy, including travel distance, caregiver availability, and time away from home.
Dr. Joshua Richter and Dr. Marco Davila discuss the importance of collaboration between specialized cellular therapy centers and community oncologists to improve access to CAR T-cell therapy for patients with relapsed/refractory multiple myeloma (RRMM).
Dr. Joshua Richter and Dr. Marco Davila discuss how to prepare patients with relapsed/refractory multiple myeloma (RRMM) for the CAR T-cell therapy process by setting clear expectations before treatment begins.
Dr. Joshua Richter and Dr. Marco Davila discuss the importance of aligning treatment decisions with individual patient goals in relapsed/refractory multiple myeloma (RRMM), particularly among older adults being considered for CAR T-cell therapy.
Dr. Joshua Richter and Dr. Marco Davila discuss the rationale for incorporating CAR T-cell therapy earlier in the treatment course for relapsed/refractory multiple myeloma (RRMM).
Dr. Joshua Richter and Dr. Marco Davila present a case of a patient with relapsed/refractory multiple myeloma (RRMM) experiencing first relapse after initial therapy and discuss whether patients considered ineligible for autologous stem cell transplantation may still be candidates for CAR T-cell therapy.
Dr. Joshua Richter and Dr. Marco Davila discuss the essential role of multidisciplinary care and caregiver engagement in the management of relapsed/refractory multiple myeloma (RRMM), particularly for patients undergoing CAR T-cell therapy.
Dr. Joshua Richter and Dr. Marco Davila discuss how to counsel patients with relapsed/refractory multiple myeloma (RRMM) about recovery and long-term follow-up after CAR T-cell therapy.
Dr. Joshua Richter and Dr. Marco Davila discuss practical strategies for bridging therapy in relapsed/refractory multiple myeloma (RRMM) as patients transition to CAR T-cell therapy.
Dr. Joshua Richter and Dr. Marco Davila discuss the ideal timing for referral to a cellular therapy specialist for patients with relapsed/refractory multiple myeloma (RRMM).
Dr. Joshua Richter and Dr. Marco Davila discuss how clinicians determine the optimal timing for CAR T-cell therapy in relapsed/refractory multiple myeloma (RRMM), emphasizing that treatment decisions should be individualized rather than based solely on line of therapy.
Dr. Joshua Richter and Dr. Marco Davila examine how real-world evidence is shaping the use of CAR T-cell therapy for relapsed/refractory multiple myeloma (RRMM) beyond the results of pivotal clinical trials.
Experts unpack relapsed myeloma sequencing—risk, refractoriness, and support—plus earlier CAR T and bispecifics shaping personalized care.
Experts unpack relapsed myeloma sequencing—risk factors, referrals, and earlier CAR‑T and bispecific therapies to personalize care and support patients.
Marco Davila, MD, PhD, discusses how a study of tumor drivers of CAR T-cell therapy resistance in LBCL may promote future biomarker investigations.
Marco Davila, MD, PhD, discusses research investigating ways to combat immune escape mechanisms in LBCL treated with CD19-directed CAR T-cell therapy.
Marco Davila, MD, PhD, discusses emerging strategies to overcome resistance to CD19-directed CAR T-cell therapy in aggressive large B-cell lymphoma.
Marco Davila, MD, PhD, explains the role of intrinsic tumor drivers in CD19 CAR T-cell therapy resistance in aggressive large B-cell lymphoma.
Marco Davila, MD, PhD, discusses how to shape the future of medicine with gene and cell therapy.
